Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Neoplasms by Site 3Colorectal Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Digestive System Neoplasms 2Digestive System Diseases 2Carcinoma, Non-Small-Cell Lung 2Thymus Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Neoplasms 1Rectal Diseases 1Pancreatic Neoplasms 1Pancreatic Diseases 1Mesothelioma, Malignant 1Lung Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Colonic Diseases 1Carcinoma, Pancreatic Ductal 1Carcinoma, Hepatocellular 1Bronchial Neoplasms 1Advanced Gastrointestinal Cancer 1

Interventions

pembrolizumab 2ribociclib 1napabucasin 1epacadostat 1amrubicin 1Sunitinib 1Plicamycin 1Paclitaxel 1Nivolumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Thymus Neoplasms × napabucasin × Clear all
NCT01325441 2023-11-15

A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies

Sumitomo Pharma America, Inc.

Phase 1/2 Completed
565 enrolled 17 charts

Neoplasms, Thymus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡